PharmaFocus Today – Page 72 – media

Haisco has been approved to conduct clinical trials of its independently developed HSK47388 tablets

August 7, Haisco(002653) issued an announcement that the company recently received the “Notice of Approval for Drug Clinical Trial” issued by the National Medical Products Administration, approving its independently developed innovative drugClinical trials are underway for HSK47388 tablets, a Class 1 chemical drug intended for the treatment of autoimmune diseases. According to the announcement, HSK47388 tablets demonstrated dose-dependent inhibition of inflammatory responses in preclinical studies, with good tolerability and safety, and are expected to provide a new treatment option for patients with autoimmune diseases. The company will continue to monitor the progress of this project and fulfill its corresponding information disclosure obligations. In the first quarter of 2025, Haisco achieved revenue of 892 million yuan and net profit attributable to shareholders of the parent company of 46.61 million yuan. https://finance.eastmoney.com/a/202508073478877223.html
- Source: drugdu
- 177
- August 9, 2025
Sino Biopharmaceutical’s Rovaxin tablets included in the breakthrough therapy program

On August 6, Sino Biopharmaceutical Co., Ltd. issued an announcement stating that the group’s independently developed rovacitinib tablets “TQ05105 (JAK/ROCK inhibitor)” have been included in the Breakthrough Therapy Drug Program (BTD) by the Drug Review Center of the China National Medical Products Administration (CDE) for the treatment of chronic graft-versus-host disease (cGVHD). This event indicates that the drug has significant advantages in treating chronic graft-versus-host disease and is expected to accelerate its approval and marketing. This will enhance the company’s future performance expectations, strengthen investor confidence, and further enhance the company’s competitiveness and valuation in the capital market. https://finance.eastmoney.com/a/202508063477733776.html
- Source: drugdu
- 178
- August 9, 2025
BeiGene achieves first half-year profit

On August 6, BeiGene announced its second-quarter 2025 US stock results and key semi-annual financial data for its A-share listings. In the first half of 2025, BeiGene achieved total operating revenue of 17.518 billion yuan, a year-on-year increase of 46.0%. Product revenue reached 17.360 billion yuan, a year-on-year increase of 45.8%. Net profit attributable to the parent company was 450 million yuan, marking the company’s first-half year return to profitability. These first-half results demonstrate significant breakthroughs in product sales and market expansion, which will significantly boost investor confidence, drive stock price appreciation, enhance the company’s valuation and attractiveness in the capital markets, and lay a solid foundation for future financing and development. https://finance.sina.com.cn/roll/2025-08-08/doc-infkfkhi3879307.shtml
- Source: drugdu
- 128
- August 8, 2025
Buchang Pharmaceuticals has appointed an exclusive distributor in the Philippines for a new drug

On August 7, Buchang Pharmaceutical issued an announcement stating that its controlling subsidiary Luzhou Buchang intends to sign an “Exclusive Supply Agreement” with the Philippine company GOODFELLOW, authorizing the latter to serve as the exclusive agent in the Philippines to complete the registration, related clinical trials, promotion, distribution and sales of the Class I new therapeutic biological drug – Efparepoetin alfa for injection. This transaction is another breakthrough in the internationalization process of Stepan Pharmaceutical’s strategic layout of biopharmaceuticals. While bringing economic benefits to the company, it will also help enhance the company’s brand value and have a good driving effect on enhancing the company’s core competitiveness. https://jnzstatic.cs.com.cn/zzb/htmlInfo/101481.html
- Source: drugdu
- 196
- August 8, 2025
Eli Lilly’s oral drug orforglipron (36 mg) resulted in an average weight loss of 12.4 kg

On August 7, Eli Lilly announced positive top-line results from the Phase 3 ATTAIN-1 clinical study. In ATTAIN-1, orforglipron achieved its primary endpoint, demonstrating significantly greater weight loss compared to placebo. At week 72, the highest dose (36 mg) of orforglipron achieved an average weight loss of 12.4 kg. These positive results are expected to bolster market confidence in Eli Lilly’s weight loss strategy, boost its valuation, and strengthen its position in future market competition, attracting greater investor attention. https://www.zhihuiya.com/news/info_10392.html
- Source: drugdu
- 107
- August 8, 2025
AI pharmaceutical leader wins big order worth 47 billion

Recently, Jingtai Technology announced that it has signed a pipeline collaboration agreement with DoveTree for a total order value of approximately HK$47 billion (US$5.99 billion), and has received an initial payment of approximately HK$400 million (US$51 million) as agreed in the agreement. This collaboration sets a new record for order size in the field of artificial intelligence (AI) and robotics-based new drug development. According to the terms of the agreement, Jingtai Technology and DoveTree have reached a cooperation on a number of large molecule and small molecule innovative drug assets in the preclinical stage, and will conduct new drug research and development for a series of DoveTree-designated targets. DoveTree exclusively enjoys the exclusive global development and commercialization rights of the relevant drugs. In return, in addition to the upfront payment, Jingtai Technology is entitled to receive a further payment of approximately HK$385 million (US$49 million), as well as potential milestone ...
- Source: drugdu
- 183
- August 8, 2025
Pfizer is brewing the next outbreak

Three years after the COVID-19 pandemic subsided, global pharmaceutical giant Pfizer has changed direction and is betting heavily on the next generation of anti-tumor therapies. Can it return to its peak? Q2 performance exceeded expectations, with revenue increasing by 10% year-on-year According to Pfizer’s latest financial report, its second-quarter 2025 revenue reached $14.7 billion, a 10% year-over-year increase, exceeding market expectations. Its first-half revenue reached $28.37 billion, a 1% year-over-year increase. Pfizer forecast full-year revenue of $61 billion to $64 billion and raised its 2025 full-year EPS guidance by $0.10 to a range of $2.90 to $3.10. From the perspective of business segments, Primary Care, Specialty Care and Oncology businesses generated revenues of US$5.54 billion (12%), US$4.378 billion (+7%) and US$4.387 billion (+11%) in the second quarter, respectively. Looking at specific products, within the Primary Care segment, the anticoagulant Eliquis (apixaban) contributed over $2 billion in Q2, a 6% year-over-year ...
- Source: drugdu
- 243
- August 8, 2025
Vitamin D supplementation linked to improved cardiometabolic health

A latest systematic review and meta-analysis conducted by scientists from institutions across China and the United States has uncovered promising insights into how vitamin D supplementation can significantly impact cardiometabolic health. The study, which was published in Engineering, has implications for tailored therapeutic strategies targeting cardiovascular diseases and related risks. The comprehensive review analyzed 99 randomized controlled trials (RCTs) involving a total of 17 656 participants. The analysis revealed that vitamin D supplementation, with a median dose of 3320 International Units (IU) per day, was associated with favorable effects on various cardiometabolic risk factors, including reductions in systolic and diastolic blood pressure, total cholesterol, fasting blood glucose, hemoglobin A1C, and fasting blood insulin. Significantly, the researchers discovered that the benefits of vitamin D supplementation were most pronounced in specific groups: non-Western populations, individuals with baseline 25-hydroxyvitamin D levels below 15.0 ng·mL−1, those with a body mass index (BMI) below 30 ...
- Source: drugdu
- 166
- August 7, 2025
Dizzy, Heart Racing After You Stand? New Treatment Proposed

By Dennis Thompson HealthDay ReporterWEDNESDAY, Aug. 6, 2025 (HealthDay News) — Some people find that when they stand, their hearts tend to race and they get dizzy and lightheaded. This is due to a rare condition called postural orthostatic tachycardia syndrome, or POTS – and doctors think they’ve found a potential treatment. An established heart failure drug called ivabradine appears to provide lasting relief for people suffering from POTS, according to results from a pilot study. The drug kept POTS patients’ hearts from racing and significantly improved other symptoms while not affecting their overall blood pressure, researchers recently reported in the Journal of Cardiovascular Pharmacology. “These data suggest that the inappropriate increase in heart rate is exactly why patients feel sick, and that reducing the heart rate with a medication that does not affect blood pressure can make a difference in the quality of life,” senior researcher Dr. Antonio ...
- Source: drugdu
- 132
- August 7, 2025
Announcement on Obtaining Orphan Drug Designation from the U.S. FDA

On the evening of August 6, Hengrui MedicineThe company recently received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its Ruikang trastuzumab injection, combined with adebelimumab injection and chemotherapy, for the treatment of gastric cancer or gastroesophageal junction adenocarcinoma. Orphan drugs, also known as rare disease drugs, are used to prevent, treat, or diagnose rare diseases. This FDA orphan drug designation provides the company with opportunities to benefit from U.S. policy support in product development, registration, and commercialization. https://finance.eastmoney.com/a/202508063477857963.html
- Source: drugdu
- 164
- August 7, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.